Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2004
  • Online publication date: December 2009

7 - The science of quality-of-life measurement in lung cancer

Summary

Introduction

Lung cancer is the leading cause of cancer death in the US. Non-small-cell lung cancer (NSCLC) (squamous, adenocarcinoma, and large cell carcinoma) is responsible for about 75% of these cases, while small cell lung cancer (SCLC) accounts for the other 25%. Most patients present with incurable disease at the time of diagnosis and, because of early hematogenous spread, even those presenting with “early” stage disease will usually eventually develop incurable metastases. The five-year survival rate for all lung cancer patients is only 15% and has not improved significantly over the last 30 years.

Surgery is the only treatment modality that can consistently cure a small number of patients with early NSCLC, although radiation can be curative in some limited circumstances. Chemotherapy may contribute in an adjuvant or neoadjuvant role, but it is mostly used as a palliative therapy for advanced disease. SCLC, on the other hand, is more chemosensitive and can be cured in a minority of patients with chemotherapy and radiation. Nevertheless, most patients relapse and die within one year of diagnosis.

Treatments for all stages and histologies of lung cancer are difficult, expensive, and come with non-trivial toxicity. Because the prognosis is almost uniformly poor despite intervention, many of these therapies are controversial. At presentation, over 80% of lung cancer patients report disease-related symptoms, most commonly cough and dyspnea, as well as systemic effects like fatigue and anorexia and high degrees of psychological distress.

REFERENCES
Greenlee, R. T., Murray, T., Bolden, S.et al. (2000). Cancer statistics, 2000Ca: Cancer Journal for Clinicians 50:7–33
DeVita, V. T. Jr., Hellman, S., Rosenberg, S. A. (1993). Cancer: Principles and Practice of Oncology. Philadelphia, PA: J.B. Lippincott Co
Reis, L. A. G., Kosary, C. L., Hankey, B. F. et al. (1999). SEER Cancer Statistics Review, 1973–1996. Bethesda, MD: National Cancer Institute
Hopwood, P., Stephens, R. J. (1995). Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatmentBritish Journal of Cancer 71:633–6
Thatcher, N., Hopwood, P., Anderson, H. (1997). Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabineEuropean Journal of Cancer 33:S8–13
Hollen, P. J., Gralla, R. J. (1996). Comparison of instruments for measuring quality of life in patients with lung cancerSeminars in Oncology 23:31–40
Hopwood, P. (1996). Quality of life assessment in chemotherapy trials for non-small cell lung cancer: are theory and practice significantly different?Seminars in Oncology 23:60–4
Manegold, C., Schwarz, R. (1996). Quality of life and supportive care in the treatment of NSCLCChest 109:113S–14S
Johnson, D. H. (2000). Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: a historical perspective and the eastern cooperative oncology group experienceChest 117:133S–7S
Chang, A. Y., Kim, K., Boucher, H.et al. (1998). A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587)Cancer 82:292–300
Crawford, J., O'Rourke, M., Schiller, J. H.et al. (1996). Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancerJournal of Clinical Oncology 14:2774–84
Li, B., Yu, J., Suntharalingam, M.et al. (2000). Comparison of three treatment options for single brain metastasis from lung cancerInternational Journal of Cancer 90:37–45
White, S. C., Cheeseman, S., Thatcher, N.et al. (2000). Phase II study of oral topotecan in advanced non-small cell lung cancerClinical Cancer Research 6:868–73
Hopwood, P., Harvey, A., Davies, J.et al. (1998). Survey of the administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering CommitteeEuropean Journal of Cancer 34:49–57
Sarna, L. (1993). Correlates of symptom distress in women with lung cancerCancer Practice 1:21–8
Sarna, L. (1993). Women with lung cancer: impact on quality of lifeQuality of Life Research 2:13–22
Sarna, L., Brecht, M. L. (1997). Dimensions of symptom distress in women with advanced lung cancer: a factor analysisHeart Lung 26:23–30
Movsas, B., Scott, C., Sause, W.et al. (1999). The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studiesInternational Journal of Radiation Oncology, Biology, and Physics 45:1143–9
Erickson, this volume, Chapter 3
Hendriks, J., Schil, P., Meerbeeck, J.et al. (1996). Short-term survival after major pulmonary resections for bronchogenic carcinomaActa Chirurgica Belgica 96:273–9
Taenzer, P., Bultz, B. D., Carlson, L. E.et al. (2000). Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatientsPsycho-Oncology 9:203–13
Lutz, S. T., Huang, D. T., Ferguson, C. L.et al. (1997). A retrospective quality of life analysis using the Lung Cancer Symptom Scale in patients treated with palliative radiotherapy for advanced nonsmall cell lung cancerInternational Journal of Radiation Oncology, Biology, and Physics 37:117–22
Bernhard, J., Hurny, C., Bacchi, M.et al. (1996). Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK)British Journal of Cancer 74:1660–7
Joss, R. A., Alberto, P., Hurny, C.et al. (1995). Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)Annals of Oncology 6:41–8
Montazeri, A., Milroy, R., Hole, D.et al. (1998). Anxiety and depression in patients with lung cancer before and after diagnosis: findings from a population in Glasgow, ScotlandJournal of Epidemiology and Community Health 52:203–4
Cullen, M. H., Billingham, L. J., Woodroffe, C. M.et al. (1999). Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of lifeJournal of Clinical Oncology 17:3188–94
Helsing, M., Bergman, B., Thaning, L.et al. (1998). Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study GroupEuropean Journal of Cancer 34:1036–44
Gridelli, C., Frontini, L., Perrone, F.et al. (2002). Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin InvestigatorsBritish Journal of Cancer 83:707–14
Aaronson, N. K., Cull, A. M., Kaasa, S., Sprangers, M. A. G. (1996). The European Organization for Research and Treatment of Cancer (EORTC) modular approach to quality of life assessment in oncology: an update. In Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edition), ed. B. Spilker, pp. 179–89. Philadelphia, PA: Lippincott-Raven
Cella, D. F., Bonomi, A. E. (1996). The Functional Assessment of Cancer Therapy (FACT) and Functional Assessment of HIV Infection (FAHI) quality of life measurement system. In Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edition), ed. B. Spilker, pp. 203–14. Philadelphia, PA: Lippincott-Raven
European Organization for Research and Treatment of Cancer. QLQ-C30 (core). http://www.eortc.be/home/qol/ Accessed September 10, 2004
Bergman, B., Aaronson, N. K., Ahmedzai, S.et al. (1994). The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of LifeEuropean Journal of Cancer 30A:635–42
Bergman, B., Sullivan, M., Sorenson, S. (1992). Quality of life during chemotherapy for small cell lung cancer. II. A longitudinal study of the EORTC Core Quality of Life Questionnaire and comparison with the Sickness Impact ProfileActa Oncologica 31:19–28
Herndon, J. E., Fleishman, S., Kosty, M. P.et al. (1997). A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931Controlled Clinical Trials 18:286–300
Kosmidis, P. (1996). Quality of life as a new end pointChest 109:110S-2S
Aaronson, N. K., Ahmedzai, S., Bergman, B.et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncologyJournal of the National Cancer Institute 85:365–76
Osoba, D., Zee, B., Pater, J.et al. (1994). Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancerQuality of Life Research. 3:353–64
Osoba, D., Murray, N., Gelmon, K.et al. (1994). Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapyOncology (Huntington) 8:61–5
Geddes, D. M., Dones, L., Hill, E.et al. (1990). Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trialEuropean Journal of Cancer 26:484–92
Zieren, H. U., Muller, J. M., Hamberger, U.et al. (1996). Quality of life after surgical therapy of bronchogenic carcinomaEuropean Journal of Cardiovascular Therapy 10:233–7
Cella, D. F., Tulsky, D. S., Gray, G. S. B.et al. (1993). The Functional Assessment of Cancer Therapy Scale: development and validation of the general measureJournal of Clinical Oncology 11:570–9
Cella, D. F., Tulsky, D. S., Gray, G. S. B. et al. Functional Assessment of Chronic Illness Therapy. http://www.facit.org. Accessed September 10, 2004
Cella, D. F., Bonomi, A. E., Lloyd, S. R.et al. (1995). Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrumentLung Cancer 12:199–220
Bonomi, P., Kim, K., Fairclough, D.et al. (2000). Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trialJournal of Clinical Oncology 18:623–31
Colon-Otero, G., Niedringhaus, R. D., Hillman, S. H.et al. (2001). A phase II trial of edatrexate, vinblastine, adriamycin, cisplastin, and filgrastim (EVAC/G-CSF) in patients with non-small-cell carcinoma of the lungs: a North Central Cancer Treatment Group TrialAmerican Journal of Clinical Oncology 24:551–5
Hollen, P. J., Gralla, R. J., Kris, M. G.et al. (1993). Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS)European Journal of Cancer 29A(Suppl. 1):S51–8
Hollen, P. J., Gralla, R. J., Kris, M. G.et al. (1994). Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS)Supportive Care in Cancer 2:213–22
Hollen, P. J., Gralla, R. J., Kris, M. G.et al. (1994). Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom ScaleCancer 73:2087–98
Hollen, P. J., Gralla, R. J., Kris, M. G.et al. (1999). Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS)Supportive Care in Cancer 7:140–8
Hollen, P. J., Gralla, R. J., Liepa, A. M.et al. (2001). Validation of a quality of life instrument for patients with pleural mesothelioma: Lung Cancer Symptom ScaleProceedings of the American Society for Clinical Onology 20 (Abstract 1579)
Lung Cancer Symptom Scale. http://www.lcss-ql.com/. Accessed September 10, 2004
Hollen, P. J., Gralla, R. J., Cox, C.et al. (1997). A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancerLung Cancer 18:119–36
Dales, R. E., Belanger, R., Shamji, F. M.et al. (1994). Quality-of-life following thoracotomy for lung cancerJournal of Clinical Epidemiology 47:1443–9
Langendijk, J. A., ten Velde, G. P., Aaronson, N. K.et al. (2002). Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective studyInternational Journal of Radiation Oncology, Biology, and Physics 47:149–55
Schaafsma, J., Coy, P. (2000). Response of global quality of life to high-dose palliative radiotherapy for non-small-cell lung cancerInternational Journal of Radiation Oncology, Biology, and Physics 47:691–701
Lutz, S., Norrell, R., Bertucio, C.et al. (2001). Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospitalJournal of Palliative Medicine 4:157–65
Hickish, T. F., Smith, I. E., Nicolson, M. C.et al. (1998). A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancerBritish Journal of Cancer 77:1966–70
Shevlin, P. M., Muers, M. F., Peake, M. D.et al. (1998). Modified ICE study: a phase II study of an intensive, modified ICE regimen (ifosfamide, carboplatin and etoposide) in patients with better prognosis, small cell lung cancerLung Cancer 21:115–26
Frasci, G., Comella, P., Panza, N.et al. (1998). Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-ItaliaEuropean Journal of Cancer 34:1710–14
Tester, W. J., Jin, P. Y., Reardon, D. H.et al. (1997). Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusionCancer 79:724–9
Roychowdhury, D. F., Desai, P., Zhu, Y. W. (1997). Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancerSeminars in Oncology 24:S12.
Han, J. Y., Kim, H. K., Choi, B. G.et al. (1998). Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide and cisplatin) chemotherapy in advanced non-small cell lung cancers (NSCLC)Japanese Journal of Oncology 28:749–53
Gridelli, C., Perrone, F., Gallo, C.et al. (1999). Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trialAnticancer Research 19:4535–8
Kosmas, C., Tsavaris, N. B., Polyzos, A.et al. (2000). A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinomaCancer 89:774–82
Socinski, M. A., Steagall, A., Gillenwater, H. (1999). Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trialCancer Investigation 17:181–8
Pujol, J. L., Monnier, A., Berille, J.et al. (1994). Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancerBritish Journal of Cancer 69:1136–40
Maasilta, P. K., Rautonen, J. K., Mattson, M. T.et al. (1990). Quality of life assessment during chemotherapy for non-small cell lung cancerEuropean Journal of Cancer 26:706–8
Quantin, X., Riviere, A., Daures, J. P.et al. (2000). Phase I-II study of high dose epirubicin plus cisplatin in unresectable non-small-cell lung cancer: searching for the maximal tolerated doseAmerican Journal of Clinical Oncology 23:192–6
Buccheri, G., Ferrigno, D. (2000). Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma: a phase II studyCancer 88:2677–85
Hurny, C., Bernhard, J., Joss, R.et al. (1993). “Fatigue and malaise” as a quality-of-life indicator in small-cell lung cancer patients. The Swiss Group for Clinical Cancer Research (SAKK)Supportive Care in Cancer 1:316–20
Tishelman, C., Degner, L. F., Mueller, B. (2000). Measuring symptom distress in patients with lung cancer. A pilot study of experienced intensity and importance of symptoms [published erratum appears in Cancer Nursing (2000)23(3):163]Cancer Nursing 23:82–90
The Elderly Lung Cancer Vinorelbine Italian Study Group (1999). Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancerJournal of the National Cancer Institute 91:66–72
Regan, J., Yarnold, J., Jones, P. W.et al. (1991). Palliation and life quality in lung cancer: how good are clinicians at judging treatment outcome?British Journal of Cancer 64:396–400
Gralla, R. J., Hollen, P. J., Rittenberg, C. N.et al. (1999). Measuring quality of life (QL) in lung cancer clinical trials: Determining the frequency of QL assessmentProceedings of the American Society for Clinical Oncology 18 (Abstract 2235)
Hurny, C., Bernhard, J., Joss, R.et al. (1992). Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer — a lesson from the real world — the Swiss Group for Clinical Cancer Research SAKKAnnals of Oncology 3:825–31
Bergman, B., Sullivan, M., Sorenson, S. (1991). Quality of life during chemotherapy for small cell lung cancer. I. An evaluation with generic health measuresActa Oncologica 30:947–57
Hopwood, P., Stephens, R. J., Machin, D. (1994). Approaches to the analysis of quality of life data: experiences gained from a medical research council lung cancer working party palliative chemotherapy trialQuality of Life Research 3:339–52
Kosty, M. P., Fleishman, S. B., Herndon, J. E.et al. (1994). Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group BJournal of Clinical Oncology 12:1113–20
Giaccone, G., Splinter, T. A., Debruyne, C.et al. (1998). Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative GroupJournal of Clinical Oncology 16:2133–41
Earl, H. M., Rudd, R. M., Spiro, S. G.et al. (1991). A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trialBritish Journal of Cancer 64:566–72
Ahles, T. A., Silberfarb, P. M., Rundle, A. C.et al. (1994). Quality of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for cancer and leukemia group BPsychotherapy and Psychosomatics 62:193–9
Macbeth, F. R., Bolger, J. J., Hopwood, P.et al. (1996). Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working PartyClinical Oncology (Royal College of Radiology) 8:167–75
Bailey, A. J., Parmar, M. K., Stephens, R. J. (1998). Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated radiotherapy (CHART) randomized trial in non-small-cell lung cancer. CHART Steering CommitteeJournal of Clinical Oncology 16:3082–93
Anderson, H., Hopwood, P., Stephens, R. J.et al. (2000). Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung CancerBritish Journal of Cancer 83:447–53
Agteresch, H. J., Dagnelie, P. C., Gaast, A.et al. (2000). Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancerJournal of the National Cancer Institute 92:321–8
Shepherd, F. A., Dancey, J., Ramlau, R.et al. (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyJournal of Clinical Oncology 18:2095–103
Roszkowski, K., Pluzanska, A., Krzakowski, M.et al. (2000). A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)Lung Cancer 27:145–57
Ranson, M., Davidson, N., Nicolson, M.et al. (2000). Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancerJournal of the National Cancer Institute 92:1074–80
Souhami, R. L., Spiro, S. G., Rudd, R. M.et al. (1997). Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapyJournal of National Cancer Institute 89:577–80
Gower, N. H., Rudd, R. M., Ruiz de Elvra, M. C.et al. (1995). Assessment of ‘quality of life’ using a daily diary card in a randomised trial of chemotherapy in small-cell lung cancerAnnals of Oncology 6:575–80
Fayers, P. M., Bleehen, N. M., Girling, D. J.et al. (1991). Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working PartyBritish Journal of Cancer 64:299–306
Frasci, G., Lorusso, V., Panza, N.et al. (2000). Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancerJournal of Clinical Oncology 18:2529–36
ten Bokkel, H., Bergman, B., Chemaissani, A.et al. (1999). Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancerLung Cancer 26:85–94
Rowland, K. M. J., Loprinzi, C. L., Shaw, E. G.et al. (1996). Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group studyJournal of Clinical Oncology 14:135–41
Loprinzi, C. L., Goldberg, R. M., Su, J. Q.et al. (1994). Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancerJournal of Clinical Oncology 12:1126–9
Thatcher, N., Girling, D. J., Hopwood, P.et al. (2000). Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working PartyJournal of Clinical Oncology 18:395–404
Crino, L., Scagliotti, G. V., Ricci, S.et al. (1999). Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer ProjectJournal of Clinical Oncology 17:3522–30
Cardenal, F., Lopez-Cabrerizo, M. P., Anton, A.et al. (1999). Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancerJournal of Clinical Oncology 17:12–18
Kosmidis, P., Mylonakis, N., Fountzilas, G.et al. (1997). Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized studySeminars in Oncology 24:S12
Glimelius, B., Birgegard, G., Hoffman, K.et al. (1992). Improved care of patients with small cell lung cancer. Nutritional and quality of life aspectsActa Oncologica 31:823–31
Fairclough, this volume, chapter 17
Gelber, R. D., Goldhirsch, A., Cole, B. F.et al. (1996). A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancerJournal of the National Cancer Institute 88:1039–45
Goldhirsch, A., Gelber, R. D., Simes, R. J.et al. (1989). Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysisJournal of Clinical Oncology 7:36–44
Patrick, D. L., Starks, K. C., Cain, R. F.et al. (1994). Measuring preferences for health states worse than deathMedical Decision Making 14:9–18
Hyodo, I., Eguchi, K., Takigawa, N.et al. (1999). Psychological impact of informed consent in hospitalized cancer patients. A sequential study of anxiety and depression using the hospital anxiety and depression scaleSupportive Care in Cancer 7:396–9
Hopwood, P., Stephens, R. J. (2000). Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life dataJournal of Clinical Oncology 18:893–903
Faller, H., Bulzebruck, H., Drings, P.et al. (1999). Coping, distress, and survival among patients with lung cancerArchives of General Psychiatry 56:756–62
McCarthy, E. P., Phillips, R. S., Zhong, Z. (2000). Dying with cancer: patients' function, symptoms, and care preferences as death approachesJournal of the American Geriatric Society 48:S110–21
Claessens, M. T., Lynn, J., Zhong, Z.et al. (2000). Dying with lung cancer or chronic obstructive pulmonary disease: insights from SUPPORT. Study to Understand Prognoses and Preferences for Outcomes and Risks of TreatmentsJournal of the American Geriatric Society 48:S146–53
Schag, C. A., Ganz, P. A., Wing, D. S.et al. (1994). Quality of life in adult survivors of lung, colon and prostate cancerQuality of Life Research 3:127–41
Degner, L. F., Sloan, J. A. (1995). Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancerJournal of Pain and Symptom Management 10:423–31
Ganz, P. A., Lee, J. J., Siau, J. (1991). Quality of life assessment. An independent prognostic variable for survival in lung cancerCancer 67:3131–5
Ruckdeschel, J. C., Piantadosi, S. (1994). Quality of life in lung cancer surgical adjuvant trialsChest 106:324S–8S
Abratt, R., Viljoen, G. (1995). Assessment of quality of life by clinicians — experience of a practical method in lung cancer patientsSouth African Medical Journal 85:896–8
Buccheri, G. F., Ferrigno, D., Tamburini, M.et al. (1995). The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancerLung Cancer 12:45–58
Langendijk, H., Aaronson, N. K., Jong, J. M.et al. (2000). The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapyRadiotherapy and Oncology 255:19–25
Burris, H. A., Moore, M. J., Andersen, J. S.et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJournal of Clinical Oncology 15:2403–13
Vansteenkiste, J. F., Vandebroek, J. E., Nackaerts, K. L.et al. (2001). Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomized phase II study of single agent gemcitabine versus cisplatin-vindesineAnnals of Oncology 12:1221–30